Novel inhibitors of cell adhesion molecule expression
摘要:
2-Alkylsulfinyl-1,3,4-oxadiazoles have been identified as novel inhibitors of cell adhesion molecule expression on endothelial cells. These compounds have been shown to inhibit the up-regulation of ELAM-1 and VCAM-1 on activated human umbilical vein endothelial cells (HUVECs) as measured by ELISA. Copyright (C) 1996 Elsevier Science Ltd
Novel inhibitors of cell adhesion molecule expression
摘要:
2-Alkylsulfinyl-1,3,4-oxadiazoles have been identified as novel inhibitors of cell adhesion molecule expression on endothelial cells. These compounds have been shown to inhibit the up-regulation of ELAM-1 and VCAM-1 on activated human umbilical vein endothelial cells (HUVECs) as measured by ELISA. Copyright (C) 1996 Elsevier Science Ltd
Compounds of formula (I)
Z-Ar
1
—Ar
2
(I)
wherein Z is a diazabicyclic amine, Ar
1
is a 5- or 6-membered aromatic ring, and Ar
2
is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
A copper-catalyzed cross-coupling of heterocyclic thiols with aryliodides is reported. The reaction was carried out in the presence of CuI (5 mol %), 1,10-phenanthroline (10 mol %) and K2CO3 (1.3 equiv) in DMF at 120 °C. A variety of heterocyclic sulfides were prepared in high selectivities and yields.
据报道,铜催化的杂环硫醇与芳基碘化物的交叉偶联。反应在120℃下在CuI(5mol%),1,10-菲咯啉(10mol%)和K 2 CO 3(1.3当量)的存在下在DMF中进行。以高选择性和高产率制备了各种杂环硫化物。
[EN] SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS<br/>[FR] DERIVES DE DIAZABICYCLOALCANE SUBSTITUES UTILISES EN TANT QUE LIGANDS AU NIVEAU DES RECEPTEURS ALPHA 7 DE L'ACETYLCHOLINE NICOTINIQUE
申请人:ABBOTT LAB
公开号:WO2005028477A1
公开(公告)日:2005-03-31
Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
Compounds of formula (I)
Z-Ar
1
—Ar
2
(I)
wherein Z is a diazabicyclic amine, Ar
1
is a 5- or 6-membered aromatic ring, and Ar
2
is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors
申请人:Abbott Laboratories
公开号:EP2316836A1
公开(公告)日:2011-05-04
Compounds of formula (I) Z-Ar1-Ar2 wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.